Acquisitions, Corporate Restructurings, and Pipeline Developments Open Opportunities for Growth - Research Report on Boston

    Acquisitions, Corporate Restructurings, and Pipeline Developments Open
  Opportunities for Growth - Research Report on Boston Scientific, Covidien,
                        Hospira, Insmed, and Thoratec

Editor Note: For more information about this release, please scroll to bottom.

PR Newswire

NEW YORK, July 4, 2013

NEW YORK, July 4, 2013 /PRNewswire/ --

Today, Wall Street Reports announced new research reports highlighting Boston
Scientific Corporation (NYSE: BSX), Covidien plc (NYSE: COV), Hospira Inc.
(NYSE: HSP), Insmed Incorporated (NASDAQ: INSM), and Thoratec Corporation
(NASDAQ: THOR). Today's readers may access these reports free of charge -
including full price targets, industry analysis and analyst ratings - via the
links below.

Boston Scientific Corporation Research Report

On June 28, 2013, Boston Scientific Corporation (Boston Scientific) announced
that it has entered into a definitive agreement to acquire Bard EP, the
electrophysiology (EP) business of C. R. Bard, Inc., for $275 million in cash.
According to the Company, the transaction supports its strategy to provide a
robust portfolio of solutions for cardiac catheter ablations and other EP
tools to diagnose and treat a variety of conditions in which the heart beats
abnormally. Further, Boston Scientific stated that Bard EP's strong commercial
team and complementary portfolio (including catheter and recording device
technologies) would enable it to better serve the rapidly growing global EP
market with a stronger and more comprehensive offering. Boston Scientific
expects to close the transaction in the second half of 2013, subject to
customary closing conditions. Upon closing of this transaction, Bard EP would
become part of the existing Boston Scientific EP business within the Company's
Rhythm Management unit. The Full Research Report on Boston Scientific
Corporation - including full detailed breakdown, analyst ratings and price
targets - is available to download free of charge at:
[http://www.wsreports.com/r/full_research_report/5649_BSX]

--

Covidien plc Research Report

On July 1, 2013, Covidien plc (Covidien) announced that it has completed the
separation of its Pharmaceuticals business. A new independent company,
Mallinckrodt plc (Mallinckrodt), now holds this spin-off business. According
to Covidien, the spin-off enables both businesses to pursue their own
strategic and operational plans, including setting optimal levels of
investment in research and development and creating business-appropriate
capital structures. José E. Almeida, Covidien Chairman, President and Chief
Executive Officer, said, "Covidien is well positioned to deliver on its
strategic initiatives, including broadening innovation focus, aggressively
managing its portfolio, capitalizing on emerging markets opportunities and
optimizing spending to provide for investments in innovation and growth." "We
are maintaining our long-term financial goals and continue to target top-line
growth at or above the markets in which we compete." The Full Research Report
on Covidien plc - including full detailed breakdown, analyst ratings and price
targets - is available to download free of charge at:
[http://www.wsreports.com/r/full_research_report/a748_COV]

--

Hospira Inc. Research Report

On June 28, 2013, Hospira Inc. (Hospira) reported that it has received a
positive opinion from the European Medicines Agency (EMA) Committee for
Medicinal Products for Human Use (CHMP), recommending the European Commission
(EC) approval of Inflectra (infliximab) for rheumatoid arthritis, inflammatory
bowel disease, and plaque psoriasis. According to Hospira, Inflectra is a
biosimilar medicine to the reference medicinal product, Remicade (infliximab),
and is the first monoclonal antibody therapy to reach a positive opinion
following review via the EMA biosimilars regulatory pathway. The Full Research
Report on Hospira Inc. - including full detailed breakdown, analyst ratings
and price targets - is available to download free of charge at:
[http://www.wsreports.com/r/full_research_report/1b4f_HSP]

--

Insmed Incorporated Research Report

On July 1, 2013, Insmed Incorporated (Insmed) announced positive developments
in both of its clinical development programs for ARIKACE or liposomal amikacin
for inhalation (LAI). Insmed reported that its Phase 3 study of once-daily
ARIKACE to treat Pseudomonas aeruginosa (Pa) in cystic fibrosis (CF) patients
conducted at 70 sites in Europe and Canada met its primary endpoint of
non-inferiority compared with twice-daily TOBI (tobramycin inhalation
solution) for relative change in forced expiratory volume in one second
(FEV[1]), measured at the end of the third treatment cycle (24 weeks) as
compared to baseline. Further, Insmed also revealed that the US Food and Drug
Administration (FDA) has designated ARIKACE as a Qualified Infectious Disease
Product (QIDP) for the treatment of Non-Tuberculous Mycobacteria (NTM) lung
infections. ARIKACE was also granted Fast Track designation by the FDA for the
treatment of NTM. The Full Research Report on Insmed Incorporated - including
full detailed breakdown, analyst ratings and price targets - is available to
download free of charge at:
[http://www.wsreports.com/r/full_research_report/9955_INSM]

--

Thoratec Corporation Research Report

On July 1, 2013, Thoratec Corporation (Thoratec) reported that it has acquired
the DuraHeart II (DH-II) ventricular assist system from Terumo Corporation
(Terumo) for an upfront cash payment of $13 million, as well as potential
future milestone payments, based on regulatory approvals and product sales, of
up to $43.5 million. Under the agreement, a team of Terumo employees will also
transition to Thoratec and will continue to be based in Ann Arbor, Michigan.
In addition, the two Companies have entered into a distribution partnership,
in which Terumo will commercialize DH-II in Japan and potentially other parts
of Asia. According to Thoratec, it intends to apply its resources and
expertise in mechanical circulatory support in order to advance the DH-II
program through product development and clinical trials. Thoratec expects a
first-in-human implant of the DH-II pump in 2016 to be followed by clinical
trials in the US and abroad. After the clinical trials, Thoratec stated that
its distribution partnership with Terumo should optimize patient access to the
DH-II technology on a worldwide basis. Thoratec expects that the acquisition
will add incremental ongoing operating expenses, primarily related to research
and development, of approximately $6 million to $7 million in the second half
of 2013. The Full Research Report on Thoratec Corporation - including full
detailed breakdown, analyst ratings and price targets - is available to
download free of charge at:
[http://www.wsreports.com/r/full_research_report/18e4_THOR]

----

EDITOR NOTES:

1.This is not company news. We are an independent source and our views do
    not reflect the companies mentioned.
2.Information in this release is fact checked and produced on a best efforts
    basis and reviewed by a CFA. However, we are only human and are prone to
    make mistakes. If you notice any errors or omissions, please notify us
    below.
3.This information is submitted as a net-positive to companies mentioned, to
    increase awareness for mentioned companies to our subscriber base and the
    investing public.
4.If you wish to have your company covered in more detail by our team, or
    wish to learn more about our services, please contact us at
    pubco@EquityNewsNetwork.com.
5.For any urgent concerns or inquiries, please contact us at
    compliance@EquityNewsNetwork.com.
6.Are you a public company? Would you like to see similar coverage on your
    company? Send us a full investors' package to
    research@EquityNewsNetwork.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This
document, article or report is prepared and authored by Equity News Network.
An outsourced research services provider has, through Chartered Financial
Analysts, only reviewed the information provided by Equity News Network in
this article or report according to the Procedures outlined by Equity News
Network. Equity News Network is not entitled to veto or interfere in the
application of such procedures by the outsourced provider to the articles,
documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the
accuracy or completeness or fitness for a purpose (investment or otherwise),
of the information provided in this document. This information is not to be
construed as personal financial advice. Readers are encouraged to consult
their personal financial advisor before making any decisions to buy, sell or
hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned
at the time of printing of this document or any error, mistake or shortcoming.
No liability is accepted by Equity News Network whatsoever for any direct,
indirect or consequential loss arising from the use of this document. Equity
News Network expressly disclaims any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance placed on
the information in this document. Equity News Network does not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the information. The
included information is subject to change without notice.

SOURCE Wall Street Reports

Contact: Contact: WSReports.com Phone #: +1-310-496-8071
 
Press spacebar to pause and continue. Press esc to stop.